The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer

Figures & data

Table 1 Baseline Characteristics

Characteristics	N=76, N (%)
Age (years)
Median (range)	59.5 (34–86)
<60	38 (50.0)
≥60	38 (50.0)
Sex
Male	40 (52.6)
Female	36 (47.4)
ECOG
0–1	66 (86.8)
2	10 (13.1)
Primary site of disease
Rectum	40 (52.6)
Sigmoid colon	16 (21.1)
Descending colon	5 (6.6)
Transverse colon	1 (1.3)
Ascending colon	14 (18.4)
Metastatic sites
Liver	51 (67.1)
Lung	46 (60.5)
Lymph node	31 (40.8)
Peritoneum	17 (22.4)
Bone	4 (5.3)
Ovary	2 (2.6)
Primary tumor surgery
Yes	53 (69.7)
No	23 (30.3)
RAS status
Wild-type	25 (32.9)
Mutant	34 (44.7)
Unknown	17 (22.4)
BRAFV600E status
Wild-type	56 ((73.7)
Mutant	1 (1.3)
Unknown	19 (25.0)
MMR status
pMMR	51 (67.1)
dMMR	2 (2.6)
Unknown	23 (30.3)
Number of prior regimens for metastatic disease
0	2 (2.6)
1	6 (7.9)
2	38 (50.0)
3	20 (26.3)
≥4	10 (13.2)
Prior chemotherapy
Oxaliplatin	65 (85.5)
Irinotecan	70 (92.1)
Capecitabine	70 (92.1)
5-Fu	27 (35.5)
S-1	24 (31.6)
Raltitrexed	36 (47.4)
Prior targeted therapy
Bevacizumab	64 (84.2)
Cetuximab	17 (22.4)
Regorafenib	15 (19.7)

Table 2 Fruquintinib-Induced Adverse Events

Adverse Events	Any grade N (%)	Grade ¾ N (%)
Any event	70 (92.1)	21 (27.6)
Hypertension	37 (48.7)	7 (9.2)
Hand-foot skin reaction	33 (43.4)	7 (9.2)
Proteinuria	21 (27.6)	1 (1.3)
Hypothyroidism	17 (22.4)	0 (0)
Diarrhea	14 (18.4)	0 (0)
Oral mucositis	13 (17.1)	1 (1.3)
Fatigue	13 (17.1)	0 (0)
Hoarseness	12 (15.8)	0 (0)
Decreased appetite	9 (11.8)	0 (0)
Thrombocytopenia	8 (10.5)	3 (3.9)
AST increase	6 (7.9)	0 (0)
Gastritis	6 (7.9)	0 (0)
Leukopenia	3 (3.9)	0 (0)
Neutropenia	3 (3.9)	1 (1.3)
ALT increase	3 (3.9)	1 (1.3)
Bilirubin increase	3 (3.9)	0 (0)
Bleeding	3 (3.9)	0 (0)
Anemia	2 (2.6)	2 (2.6)

Figure 1 Kaplan–Meier survival curves of overall survival.

Figure 2 Kaplan–Meier survival curves of progression-free survival.

Figure 3 Kaplan–Meier survival curves of OS by CEA.

Figure 4 Kaplan–Meier survival curves of OS by fruquintinib-induced hypertension.

Figure 5 Kaplan–Meier survival curves of OS by fruquintinib-induced hypothyroidism.